Effect of the N-acetyl cysteine versus placebo on prevention and control of chemotherapy induced neuropathy in patients with breast cancer

Effect of the N-acetyl cysteine versus placebo on prevention and control of chemotherapy induced neuropathy in patients with breast cancer: a triple-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N377

Enrollment

102

Registered

2021-01-25

Start date

2021-02-03

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathy. Idiopathic progressive neuropathy

Interventions

Intervention 1: Intervention group: tablet N-acetyl cysteine (manufactured by Darman Yab Daru Pharmaceutical Co.) 1200 mg twice daily one day before chemotherapy with Taxane untile one day after that.

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age: 18 to 80 years old Candidate for chemotherapy

Exclusion criteria

Exclusion criteria: History of neuropathy with grade greater than one Behavioral disorders History of chemotherapy History of asthma

Design outcomes

Primary

Measure	Time frame
Severity of neuropathy. Timepoint: Before chemotherapy and three weeks after that. Method of measurement: Using the NCI-CTCAE v4.0 scale and Visual Analog Scale (VAS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElyas Hassanzade

Hamedan University of Medical Sciences

elyas.hassanzade@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026